A new scalp cooling device appears to reduce chemotherapy-related alopecia in women with early-stage breast cancer, according to results of the SCALP* trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.
Postmenopausal women previously treated with aromatase inhibitors (AIs) for HR-positive, HER2-negative advanced breast cancer who progressed on or after mTOR inhibitor therapy may benefit from a combination of buparlisib and fulvestrant, according to findings of the BELLE-3* study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.